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Although a subject of intense research, the mechanisms underlying dopaminergic neu-
rodegeneration in Parkinson’s disease (PD) remains poorly understood. However, a broad
range of studies conducted over the past few decades, including epidemiological, genetic,
and post-mortem analysis, as well as in vitro and in vivo modeling, have contributed sig-
nificantly to our understanding of the pathogenesis of the disease. In particular, the recent
identification and functional characterization of several genes, including α-synuclein, parkin,
DJ-1, PINK1, and LRRK2, whose mutations are causative of rare familial forms of PD have
provided tremendous insights into the molecular pathways underlying dopaminergic neu-
rodegeneration. Collectively, these studies implicate aberrant mitochondrial and protein
homeostasis as key contributors to the development of PD, with oxidative stress likely act-
ing as an important nexus between the two pathogenic events. Aberrations in homeostatic
processes leading to protein aggregation and mitochondrial dysfunction may arise intrinsi-
cally in substantia nigra pars compacta dopaminergic neurons as a result of impairments
in the ubiquitin-proteasome system, failure in autophagy-mediated clearance, alterations
of mitochondrial dynamics, redox imbalance, iron mishandling, dopamine dysregulation, or
simply from the chronic pace-making activity of nigra-localized L-type calcium channels, or
extrinsically from non-autonomous sources of stress. Given the myriad of culprits impli-
cated, the pathogenesis of PD necessarily involves an intricate network of interwoven
pathways rather than a linear sequence of events. Obviously, understanding how the vari-
ous disease-associated pathways interact with and influence each other is of mechanistic
and therapeutic importance. Here, we shall discuss some key PD-related pathways and
how they are interwoven together into a tapestry of events.
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INTRODUCTION
Parkinson’s disease (PD) is a prevalent neurodegenerative move-
ment disorder affecting 1–2% of the worldwide population above
the age of 65 (Dorsey et al., 2007). Clinically, the disease is
attended by a constellation of disabling motoric deficits includ-
ing bradykinesia (slowness in movements), rigidity, and tremor
that progressively worsen with age, ultimately leading to near total
immobility. Although pathological changes are distributed in the
PD brain (Braak et al., 2003), the principal lesion that underlies
the characteristic motor phenotype of PD patients is unequiv-
ocally the loss of dopaminergic neurons in the substantia nigra
pars compacta (SNpc) of the midbrain, which normally inner-
vates the striatum. This specific pattern of neurodegeneration in
PD is often accompanied by the presence of eosinophilic intra-
cytoplasmic inclusions known as Lewy bodies (LBs) in surviving
neurons in the SN and other affected brain areas (Braak et al.,
2003). The depletion of striatal dopamine (DA) as a result of SNpc
dopaminergic neuronal loss leads to an impaired nigro-striatal
system that otherwise allows an individual to execute proper, coor-
dinated movements. Accordingly, pharmacological replacement
of brain DA via L-DOPA administration represents an effective
symptomatic recourse for the patient (especially during the initial
stages of the disease) and remains a clinical gold standard treat-
ment for PD. However,neither L-DOPA nor any currently available
therapies can slow or stop the insidious degenerative process in the
PD brain. Thus, PD remains an incurable disease. Invariably, the
debilitating nature and morbidity of the disease present signif-
icant healthcare, social, emotional, and economic problems. As
the world population rapidly ages, these problems undoubtedly
will also increase. This is definitely a worrying trend, and one
that aptly emphasizes the urgency to develop more effective treat-
ment modalities for the PD patient. Toward this endeavor, a better
understanding of the molecular mechanism(s) that underlies the
pathogenesis of PD would certainly be helpful, as the illumi-
nation of which would allow the identification and therapeutic
exploitation of key molecules/events involved in the pathogenic
process.
Although a subject of intense research, the mechanisms under-
lying PD pathogenesis remain incompletely understood. However,
a broad range of studies conducted over the past few decades,
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including epidemiological, genetic, and post-mortem analysis, as
well as in vitro and in vivo modeling, have contributed significantly
to our understanding of the pathogenesis of the disease. In par-
ticular, the recent identification and functional characterization
of several genes, including α-synuclein, parkin, DJ-1, PINK1, and
LRRK2, whose mutations are causative of rare familial forms of
PD have provided tremendous insights into the molecular path-
ways underlying dopaminergic neurodegeneration (Martin et al.,
2011). Notably, the clinical manifestations and neuro-pathology of
familial parkinsonism can often be quite indistinguishable from
sporadic cases, which fueled the widely held assumption that the
two forms of PD are likely to have shared pathogenic mecha-
nisms. Collectively, these studies consistently implicate aberrant
protein and mitochondrial homeostasis as key contributors to
the development of PD, with oxidative stress likely acting as an
important nexus between the two pathogenic events. Further,
emerging evidence also implicates a host of new pathways, includ-
ing impairments in vesicular dynamics, calcium homeostasis, and
lipid metabolism that might contribute to disease pathogenesis
in a manner that is not necessarily uncoupled from one another
or from protein and mitochondrial homeostatic processes. Thus
the molecular events underlying dopaminergic neurodegeneration
in PD appears interwoven and complex. Here, we shall review
some key PD-related events and discuss their reciprocal effects on
each other.
ABERRANT PROTEIN HOMEOSTASIS AND PD
The presence of LBs in affected regions of the PD brain in num-
bers that far exceed their occasional presence in the normal brain
arguably provides the most glaring evidence suggesting that pro-
tein homeostasis has gone awry during disease pathogenesis. As
the cell is endowed with several complex surveillance machineries
(including the chaperone, ubiquitin-proteasome, and autophagy
systems) that rapidly detect and repair faulty proteins, and also
destroy those that are beyond repair (Figure 1) (for a recent review,
please refer to Tan et al., 2009), the presence of LBs suggests
that these homeostatic response systems have failed in one way
or another in the PD brain. Support for this came from various
groups following the identification of α-synuclein, a presynap-
tic terminal-enriched protein that is prone to misfolding and
FIGURE 1 | Protein QC systems.The chaperone, ubiquitin-proteasome, and
autophagy systems function co-ordinately to maintain intracellular protein
homeostasis. The chaperones, comprising of members of the heat-shock
proteins, represent the first line of defense in ensuring the correct folding
and refolding of proteins. When a native folding state cannot be attained,
the chaperones will direct the misfolded protein for degradation by the
proteasome. Proteins that are destined for proteasome-mediated
degradation usually have a chain of ubiquitin added via a reaction cascade
that involves the ubiquitin-activating (E1), -conjugating (E2), and -ligating (E3)
enzymes, whereby successive iso-peptide linkages are formed between the
terminal residue (G76) of one ubiquitin molecule and a lysine (K) residue
(most commonly K48) within another. The (G76-K48) polyubiquitinated
substrate is then recognized by the 26S proteasome as a target for
degradation. In some cases, proteins may be modified by K63-linked
polyubiquitination, which can promote their aggregation into inclusion
bodies and their subsequent removal by autophagy. The autophagy process
involves the sequestration of substrates by a phagophore that expands into
a double-membrane structure called autophagosome that engulfs the
substrate. The autophagosome then fuses with a lysosome to form
autolysosomes, within which the inner membrane of the autophagosome is
broken down and the cargo degraded by acidic lysosomal hydrolases.
Another form of autophagy is chaperone-mediated autophagy (CMA), which
involves the direct translocation of unfolded substrate proteins across the
lysosomal membrane through the actions of a cytosolic chaperone hsc70,
and an integral lysosomal membrane receptor LACMP2A
(lysosome-associated membrane protein type 2A).
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aggregation, as a major component of LBs (Spillantini et al.,
1997). Accordingly, elucidating how α-synuclein interacts with the
various protein quality control (QC) systems to result in LB bio-
genesis would be an important cornerstone upon which a better
understanding of PD pathogenesis could be built.
We now know that all the three protein QC systems (i.e.,
chaperone, UPS, and autophagy) are actively involved in the cel-
lular management of α-synuclein. Not surprisingly, the respec-
tive inhibition of chaperone, proteasome, or autophagy func-
tion enhances the accumulation of α-synuclein and simultaneous
inhibition of these systems promotes a synergic formation of
α-synuclein-positive inclusions (Rott et al., 2008). In turn, the
accumulation of α-synuclein can exert reciprocal effects on the
various QC systems. For example, components of the Hsp70
chaperone system (Hsp70 and Hsp40) can be depleted through
their sequestration withinα-synuclein-positive aggregates (Auluck
et al., 2002). Further, aggregatedα-synuclein species can selectively
interact with the components of the proteasome complex and
concomitantly inhibit its function (Snyder et al., 2003). Finally,
α-synuclein can also inhibit macroautophagy (otherwise referred
to as “autophagy”). This was exemplified in a mouse model of PD
where α-synuclein is over-expressed. These mice exhibit signs of
autophagy inhibition that apparently occurs at a very early stage of
autophagosome formation (Winslow et al., 2010). Supporting this,
another group recently reported that α-synuclein over-expression
can result in disrupted localization and mobilization of Atg9,
a multi-spanning membrane protein whose associated vesicles
are important sources of membranes for the synthesis of early
autophagosomes, thereby providing a mechanism forα-synuclein-
induced inhibition of autophagy (Yamamoto et al., 2012). Besides
macroautophagy, α-synuclein can also affect the function of
chaperone-mediated autophagy (CMA), a specialized form of
lysosomal degradation where proteins like α-synuclein containing
a particular penta-peptide motif related to KFERQ are transported
across the lysosomal membrane via the action of the integral
membrane protein LAMP-2A that is assisted by both cytosolic
and lumenal hsc70 (Klionsky et al., 2011) (Figure 1). Membrane
bound α-synuclein species harboring disease-associated muta-
tions or those modified by DA bind to the CMA lysosomal receptor
with high affinity but are poorly translocated, which allow them
time to seed the formation of oligomeric complexes on the mem-
brane surface that consequently places the translocation complex
under siege (Cuervo et al., 2004; Martinez-Vicente et al., 2008).
The resulting blockage of uptake and degradation of CMA sub-
strates further amplifies the burden of misfolded protein load
(including α-synuclein) for the cell and perpetuates a vicious
cycle of protein aggregation that can lead to the demise of neu-
rons, especially dopaminergic neurons. Consistent with this, CMA
inhibition following L-DOPA treatment is more pronounced in
ventral midbrain cultures containing dopaminergic neurons than
in non-DA producing cortical neurons (Martinez-Vicente et al.,
2008).
It is apparent from the above that the chaperone, ubiquitin-
proteasome, and autophagy pathways all have a role to play in the
biogenesis of α-synuclein-positive LBs and thereby PD. Accord-
ingly, pharmacological or genetic inhibition of these protein QC
pathways (particularly those involved in protein degradation)
in animal models should in theory be able to recapitulate
the disease process. Although controversial, several groups have
indeed reported evidence of SN dopaminergic neurodegeneration
and associated locomotion deficits as well as the presence of neu-
ronal inclusions in rodents subjected to subcutaneous injections of
either naturally occurring or synthetic proteasome inhibitor (Lim,
2007). Using a genetic approach, Bedford et al. (2008) made simi-
lar observations in mice that are selectively depleted of functional
proteasomes in their SN, which exhibit extensive nigro-striatal
degeneration that is accompanied by the presence of α-synuclein-
positive LB-like inclusions. Likewise, targeted genetic ablation of
essential autophagy components (i.e., Atg5 or Atg7) in neural cells
of mice also results in extensive neurodegeneration and wide-
spread inclusion pathology (Hara et al., 2006; Komatsu et al.,
2006). Moreover, when autophagy is selectively disrupted in mid-
brain dopaminergic neurons, it results in abnormal presynaptic
accumulation of α-synuclein that is accompanied by dendritic and
axonal dystrophy, reduced striatal DA content, and the formation
of somatic and dendritic ubiquitinated inclusions (Friedman et al.,
2012). Importantly, these conditionally knockout mice exhibit sig-
nificant age-dependent loss of nigral dopaminergic neurons that is
accompanied by markedly decreased spontaneous motor activity
and coordination relative to controls (Ahmed et al., 2012; Fried-
man et al., 2012). Together, these studies strongly support a role for
proteasomal and lysosomal dysfunction in disease pathogenesis.
Perhaps the most direct evidence to date linking lysosomal
impairments to PD is the demonstration that loss-of-function
mutations in a gene encoding for the lysosomal P-type ATPase
named ATP13A2 cause a juvenile and early-onset form of parkin-
sonism (albeit one that is also characterized by pyramidal degen-
eration and dementia) (Ramirez et al., 2006). What is particularly
noteworthy is that the expression and toxicity of α-synuclein is
enhanced in patient-derived fibroblasts as well as in ATP13A2-
silenced primary mouse neurons as a result of impaired lyso-
somal degradation capacity arising from deficient ATPase func-
tion (Usenovic et al., 2012). Importantly, silencing of endoge-
nous α-synuclein ameliorated the toxicity in neurons depleted
of ATP13A2, suggesting that ATP13A2-induced parkinsonism
may be contributed by α-synuclein accumulation as a result
of functional impairments of the lysosome. Supporting this,
over-expression of wild type ATP13A2 suppresses α-synuclein-
mediated toxicity in C. elegans while knockdown of ATP13A2
expression promotes the accumulation of misfolded α-synuclein
in the animal (Rappley et al., 2009). Collectively, these studies
further emphasize a patho-physiological link between lysosomal
dysfunction and α-synuclein in dopaminergic neurodegeneration.
Besides α-synuclein and ATP13A2, several other PD-linked
genes have also been associated directly or indirectly to either
the ubiquitin-proteasome and/or autophagy-lysosome systems.
Among these is parkin, a ubiquitin ligase (E3) that several groups
including ours have shown to be involved in both the proteasomal
and autophagy QC systems. Parkin is a unique multifunctional E3
member capable of mediating multiple forms of ubiquitin modifi-
cations including mono-ubiquitination, K48-linked (proteasome-
associated) and K63-linked (proteasome-independent) polyubiq-
uitination (Dawson and Dawson, 2010). The fate of a parkin
substrate thus depends on the ubiquitin topology it receives. For
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example, while parkin-mediated (presumably K48-linked) ubiq-
uitination of the substrates AIMP2 and PARIS coupled them to
proteasome-mediated degradation (Ko et al., 2005; Shin et al.,
2011), we and others have shown that parkin-mediated K63-linked
ubiquitination of synphilin and mutant DJ-1 promotes their
aggregation into inclusion bodies and their subsequent removal
via autophagy (Lim et al., 2005; Olzmann et al., 2007). Thus,
parkin-mediated protein QC appears to involve both the pro-
teasome and lysosome degradation machineries. Accordingly, one
could envision that disease-associated parkin mutations that result
in the functional disruption of its activity can lead to the toxic
accumulation of both soluble (that would otherwise be cleared by
the proteasome) and/or aggregated forms (that would otherwise
be cleared by autophagy) of its broad spectrum of substrates. Not
surprisingly, the functional assignment of parkin as a ubiquitin
ligase at the turn of the century had fueled intense research into
the role of the ubiquitin-proteasome system (UPS) in PD patho-
genesis, which arguably has become less “trendy” now. In recent
years, the attention of parkin-UPS axis has shifted toward its abil-
ity to remove damaged mitochondria via a specialized form of
autophagy known as “mitophagy” (Narendra et al., 2008), a term
originally coined by Lemasters (2005). Accordingly, impairment
in mitochondrial QC due to failed mitophagy in parkin-deficient
neurons is now thought to be a key mechanism that predisposes
them to degeneration. Understanding precisely how parkin reg-
ulates mitochondrial QC and how disruptions in this process
contribute to PD pathogenesis is a current “hot” topic amongst
PD researchers that has helped rekindle widespread interest in an
“old” pathogenic culprit.
MITOCHONDRIAL DYSFUNCTION AND PD
A role for mitochondria dysfunction in the pathogenesis of PD has
long been appreciated. The idea that mitochondrial dysfunction
could contribute to the development of PD originates from the
observation by Langston et al. (1983) in the early eighties that drug
abusers exposed to 1-methyl-4-phenyl-1,2,3,4-tertahydropyridine
(MPTP),an inhibitor of mitochondrial complex I function,display
motoric features that bear uncanny resemblance to those exhibited
by sporadic PD patients. Further, through post-mortem analysis
performed as early as 1989, several groups have recorded a sig-
nificant reduction in the activity of mitochondrial complex I as
well as ubiquinone (co-enzyme Q10) in the SN of PD brains
(Schapira et al., 1989; Shults et al., 1997; Keeney et al., 2006).
Consistent with the proposed role of mitochondrial dysfunction
as a pathogenic driver of PD, mitochondrial poisoning through
the administration of toxins such as MPTP and rotenone recapit-
ulates PD-related features in animals and represents a popular
strategy to model the disease (Dauer and Przedborski, 2003).
Interesting, whereas dopaminergic neurodegeneration induced by
MPTP can be explained by the fact its conversion into its toxic
principle MPP+ endow it with the selectivity for dopaminer-
gic neurons (by virtue of the exquisite affinity MPP+ has for
DA transporters), rotenone by comparison is more broadly dis-
tributed in the brain following its administration into animals
(Betarbet et al., 2000). Despite the more systemic distribution
of rotenone in treated animals, its toxicity is mostly confined to
dopaminergic neurons, suggesting that dopaminergic neurons are
uniquely susceptible to complex I inhibition (Betarbet et al., 2000).
Similarly, impairment of mitochondrial homeostasis via genetic
ablation of TFAM, a mitochondrial transcription factor that plays
a critical role in maintaining mitochondrial DNA, in dopaminergic
neurons of mice results in an energy crisis and neurodegeneration
(Sterky et al., 2011). Moreover, the neuronal loss is progressive and
accompanied by intraneuronal cytoplasmic inclusions (albeit not
α-synuclein-positive). This interesting mouse model that rather
faithfully recapitulates the salient features of PD is popularly
known as the “MitoPark” mouse, although critics maintain that
this model is of limited therapeutic utility as the mutation is not
based on human PD genetics. Notwithstanding this, these above
studies when taken together provide compelling support for a role
of mitochondrial dysfunction in PD pathogenesis.
Less is however known about how mitochondria become defec-
tive in PD. It is important to recognize that mitochondria are not
solitary and static structures as depicted in many textbooks but
rather are dynamic and mobile organelles that constantly undergo
membrane re-modeling through repeated cycles of fusion and fis-
sion. In addition, the organelle also undergoes regulated turnover
via mitophagy when it is damaged beyond repair. It follows that
mitochondrial dysfunction can occur at different levels ranging
from organelle biogenesis, fusion/fission to mitophagy. Indeed,
genetic mutations that disrupt the function of mitochondrial
fusion/fission regulators leads to neurodegenerative diseases such
as Charcot–Marie–Tooth type 2A (Zuchner et al., 2004) and auto-
somal dominant optic atrophy (Alexander et al., 2000; Delettre
et al.,2000) although not PDper se. At least for parkin-related cases,
a mechanism underlying mitochondrial dysfunction has recently
emerged (Figure 2). Briefly, the proposed model posits that parkin
collaborates closely with another PD-linked gene known as PINK1,
a mitochondrial serine/threonine kinase, to initiate the removal
of depolarized/damaged mitochondria. A key initial event for
mitophagy to occur is the selective accumulation of PINK1 on
the outer membrane of the damaged organelle, which is otherwise
prevented by a series of sequential proteolytic events in healthy
mitochondria (Becker et al., 2012; Greene et al., 2012). In depolar-
ized mitochondria, PINK1 stabilization on the outer membrane
enables the protein to recruit parkin to the organelle, a process
that is apparently dependent on PINK1 autophosphorylation at
Ser228 and Ser402 (Okatsu et al., 2012). This event some how trig-
gers parkin self-association (Lazarou et al., 2013), which is likely to
unmask its latent activity, the consequence of which is the ubiqui-
tination and subsequent degradation of several outer membrane
protein members (Chan et al., 2011; Yoshii et al., 2011) including
the pro-fusion mitofusin proteins (Poole et al., 2010; Ziviani et al.,
2010). The degradation of mitofusins is probably critical to prevent
unintended fusion events involving damaged mitochondria and
thereby their re-entry into the undamaged mitochondrial network
from occurring. Mitophagy induction then occurs, which likely
involves parkin-mediated K63 ubiquitination that will help recruit
the autophagy adaptors HDAC6 and p62, subsequently leading
to mitochondrial clustering around the peri-nucleus region. By
virtue of their association with the autophagy process, the con-
certed actions of p62 and HDAC6 will presumably facilitate the
final removal of damaged mitochondria by the lysosome (Ding
et al., 2010; Geisler et al., 2010; Lee et al., 2010). Interestingly,
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FIGURE 2 | Model of parkin/PINK1-mediated mitophagy. In healthy
mitochondria, PINK1 imported through the outer mitochondrial membrane
(OMM) is rapidly processed and degraded. Upon mitochondrial depolarization,
PINK1 stabilization on the OMM leads to its dualautophosphorylation on
Ser228 and Ser402. This event somehow triggers parkin recruitment,
self-association, and catalytic activation. Parkin ubiquitinates several proteins
on the OMM that results in their degradation by the proteasome. Mitophagy
induction then occurs.
according to a recent report from Mizushima’s lab, mitophago-
somes may be generated in a de novo fashion on damaged mito-
chondria to initiate their removal. The authors demonstrated that
parkin recruitment on the mitochondria induces the formation
of ULK1 (Atg1) puncta (an upstream nucleation step of the hier-
archical autophagy cascade) and Atg9 structures (Itakura et al.,
2012), although it remains unclear mechanistically how parkin
participates in the de novo synthesis of isolation membrane.
Although several groups have demonstrated that PD-associated
parkin mutants are defective in supporting mitophagy due to dis-
tinct problems at recognition, transportation, or ubiquitination of
impaired mitochondria (Lee et al., 2010; Matsuda et al., 2010), a
pertinent question to ask is whether deficient mitochondrial QC
is relevant at all to the large number sporadic PD cases where
parkin is not mutated. Although this remains to be established,
it is noteworthy to mention that we and others have previously
shown that parkin dysfunction could arise in the PD brain in the
absence of apparent mutations. This could be a result of stress-
induced biochemical alterations including oxidation and nitro-
sylation, post-translational modifications or aberrant protein–
protein interaction that can either alter the catalytic function of
the E3 ligase directly, or indirectly through promoting its aggre-
gation or degradation (LaVoie et al., 2005; Wang et al., 2005).
Interestingly, normal parkin in the brain also becomes progres-
sively more detergent-insoluble (and therefore non-functional)
with aging (Pawlyk et al., 2003), which may provide an explana-
tion to why age represents a risk factor for PD. In all these cases, the
loss of parkin function is expected to compromise the efficiency
of parkin-mediated mitophagy, amongst other parkin-regulated
events. Thus deficient mitochondrial QC may not necessarily be
restricted to cases where parkin (or PINK1) is overtly mutated.
Moreover, it is also becoming increasingly clear that various other
PD-linked proteins that may appear to have disparate functions
could all influence mitochondrial homeostasis, directly or indi-
rectly (Lim et al., 2012). For example, several groups including ours
have recently found that the disease-associated LRRK2 G2019S
mutant can trigger marked mitochondrial abnormalities when
over-expressed in cultured cells and in vivo (Ng et al., 2012; Niu
et al., 2012; Wang et al., 2012). Corroborating these findings, Mort-
iboys et al. (2010) demonstrated that cells derived from LRRK2
G2019S patient exhibited similar mitochondrial abnormalities, a
phenotype that was also shared by neural cells derived from LRRK2
patients via induced pluripotent stem cell technology (Cooper
et al., 2012). More recently, investigators from Chu Lab reported
that LRRK2 elicited calcium imbalance and depletion of dendritic
mitochondria in neurons (Cherra et al., 2013). Thus, mitochon-
drial dysfunction seems to be a common denominator underlying
both familial and sporadic forms of PD.
CROSSTALK BETWEEN THE PROTEIN AND MITOCHONDRIAL
QC SYSTEMS
What is clear from the above description is that the crosstalk
between mitochondrial QC sensor and the autophagy apparatus
needs to be tightly regulated to ensure that the pool of organelles
available to energy-demanding cells such as neurons are bio-
energetically competent. Failure in autophagy will therefore be
expected to affect mitochondrial QC as much as it will affect
protein QC. Given this, it is perhaps not surprising to note the
frequent co-occurrence of mitochondrial abnormalities and inclu-
sion bodies, the latter appearance is arguably an indication of failed
autophagy function. At the same time, mitochondrial QC is also
intimately intertwined with UPS machinery. After all, the initial
stages of mitophagy involves the ubiquitination and consequent
degradation of mitofusin of several mitochondrial outer mem-
brane proteins such as Tom 20, Tom 40, Tom 70, and Omp 25
(Chan et al., 2011; Yoshii et al., 2011). To facilitate this en-bloc
removal of mitochondrial proteins, parkin activates the UPS upon
translocation to the mitochondria. This occurs by means of the
enrichment of the proteasome-linked K48-linked ubiquitination
of targeted proteins and recruitment of the proteasome to the
mitochondria, the process of which is thought to lead to the rup-
turing of the mitochondrial outer membrane in preparation for
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mitophagy induction (Chan et al., 2011;Yoshii et al., 2011). Besides
mitophagy regulation, a recent study revealed that parkin can also
potentially regulate mitochondrial biogenesis by regulating PGC-
1α expression indirectly through its ability to down-regulate PARIS
(Shin et al., 2011), which otherwise represses PGC-1α expression
transcriptionally (Scarpulla, 2008). Again, proteasome function
is at play here as the degradation of PARIS occurs via the pro-
teasome machinery following its ubiquitination by parkin (Shin
et al., 2011).
Besides parkin, other UPS-associated enzymes also participate
in mitochondrial homeostasis. For example, the E3 members,
MARCH-V and MULAN, as well as a deubiquitinating enzyme,
USP30 are active regulators of mitochondrial dynamics (Livnat-
Levanon and Glickman, 2011). All of these UPS-associated mem-
bers reside on the mitochondrial outer membrane and collectively,
they provide a link between the organelle and the proteasome.
Interestingly, inclusion bodies formed in mice depleted of func-
tional proteasomes contain mitochondria, suggesting a potential
(albeit intriguing) role for the organelle in the biogenesis of protein
inclusions (Bedford et al., 2008). In a reciprocal fashion,mitochon-
drial dysfunction can also impact proteasome function. Notably,
energy in the form of ATP is required to assemble the protea-
some complex as well as to drive the UPS machinery. Conceivably,
in times of energy crisis, the UPS may not function optimally,
which in turn may affect mitochondrial QC. Furthermore, an
inevitable consequence of aerobic respiration is the generation of
reactive oxygen species (ROS), which can modify components of
the UPS itself, including E3 ligases that utilize active thiol groups.
As alluded earlier, parkin is particularly susceptible to oxidative
modification, which alters its solubility and promotes its aggre-
gation in a manner analogous to that brought about by several
of its missense mutations (LaVoie et al., 2005; Wang et al., 2005).
Similarly, the 19S regulatory cap of the proteasome also appears
to be especially sensitive to oxidation. Indeed, the S6/Rpt3 sub-
unit of the 19S cap has been identified to be a major target of
carbonylation in cells exposed to inducers of ROS (Ishii et al.,
2005). That UPS components are prone to oxidative modifica-
tion is somewhat paradoxical, as they are ones in the first place
responsible for the efficient clearance of proteins damaged by
oxidation. Interestingly, a very recent report demonstrated that
chronic mitochondrial impairment results in the disassembly of
26S proteasome via calpain-mediated cleavage of Rpn10 that is
accompanied by a concomitant increase in 20S proteasome level
and activity (Huang et al., 2013). The authors posit that the
increased function of 20S proteasomes, which can degrade pro-
teins in an unregulated and energy-independent manner, may
help the cell clear randomly unfolded oxidized proteins that would
otherwise build up as a result of mitochondrial dysfunction. Obvi-
ously, this strategy is beneficial only for the short-term, i.e., if
chronic, unregulated protein degradation will be detrimental to
cellular survival. Taken together, it is apparent that the UPS,
autophagy, and mitochondrial systems interact with, and exert
reciprocal effects on one another, and that ROS generated by mito-
chondrial respiration can modify the function of these systems
thereby adding another layer of complexity to an already complex
relationship.
OXIDATIVE STRESS AND PD
The production of ROS is intimately associated with mitochondr-
ial function as well as with its dysfunction. As mentioned earlier,
ROS generation represents an inevitable consequence of mito-
chondrial respiration. During the process of aerobic respiration,
partial reduction of molecular oxygen to superoxide anion (O−2 )
occurs when electrons leak from the electron transport chain or
ETC (particularly at complex I). This free radical can be converted
to the highly reactive hydroxyl radical (OH•) via an iron-catalyzed
reaction known as Fenton reaction, or to peroxynitrite (ONOO−)
upon reaction with nitric oxide (NO). Both hydroxyl radical and
peroxynitrite are potent oxidants that can cause marked cellu-
lar damage by reacting with proteins, lipids, and nucleic acids.
Further, these reactive species may also target the ETC, which
results in a feed forward cycle of increasing oxidative stress and
injury.
The brain is often thought to be particularly susceptible to
oxidation-induced damage because of its high metabolic rate and
its relatively reduced capacity to replenish its post-mitotic neu-
ronal populations compared with other organs. For SN dopamin-
ergic neurons, the vulnerability toward oxidative stress is further
enhanced by the abundance of redox-active iron in this region of
the brain, as well as by the presence of DA, whose oxidation prod-
ucts are potentially cytotoxic (Graham, 1978). Notably, several
groups have reported that markers for lipid peroxidation (includ-
ing 4-hydroxynonenal and malondialdehyde), protein carbonyl
modifications and even DNA and RNA oxidation are markedly
elevated in the SN of post-mortem PD brains (Alam et al.,
1997a,b; Zhang et al., 1999), and that these ROS-induced events are
accompanied by a dramatic depletion of reduced glutathione (pre-
sumably leading to a considerably weakened antioxidant defense
system) (Sian et al., 1994). As mentioned earlier, mitochondrial
poisons that recapitulates PD features in humans and animals alike
often target complex I, the impairment of which enhances super-
oxide production and thereby the formation of highly reactive free
radicals that can initiate neuronal death. Importantly, oxidative
damage and nigral dopaminergic neurodegeneration appears to
correlate in a temporal manner in these models, suggesting a causal
role of oxidation-induced stress in PD pathogenesis (McCormack
et al., 2002; Peng et al., 2005).
Although the Redox chemistry of DA and the abundance of iron
in SN dopaminergic neurons may underlie their heightened level
of oxidative stress compared to other neuronal subtypes, another
tantalizing culprit may be a unique channel type that resides on
nigral dopaminergic neurons known as L-type Ca2+ channels.
Unlike their counterparts in the Ventral Tegmental Area (VTA),
SN dopaminergic neurons use L-type Ca2+ channels to help main-
tain autonomous pace-making (Chan et al., 2007). Because L-type
Ca2+ channels are open most of the time (as they are open at
relatively hyperpolarized state), the nigral neurons would experi-
ence a significantly larger magnitude and spatial extent of Ca2+
influx with time, which obviously comes with a price. Normally,
the level of intracellular Ca2+ is under very tight homeostatic con-
trol by the actions of ATP-dependent pumps whose operations
are metabolically expensive. A sustained entry of Ca2+ intonigral
neurons would presumably work the mitochondria machinery
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FIGURE 3 | A tapestry of molecular events in PD pathogenesis. Disruption
of mitochondrial and protein QCs can arise from overt PD-linked genetic
mutations or through oxidative modifications of their components by ROS,
the levels of which can be elevated by DJ-1 mutations, Fe2+-mediated Fenton
reaction or increased Ca2+ influx through the L-type Ca2+ channel. Because of
the crosstalk that exists between the QC systems, each can in turn affect the
other in a reciprocal fashion. Aberrant mitochondrial and protein QCs and
redox imbalance all can promote the formation of α-synuclein protofibrils and
fibrils, which in turn can block the function of the proteasome and CMA.
Aggregated α-synuclein species, if not cleared in a timely fashion, can also
seed the formation of LBs, which can be physically obstructive to neuronal
function if allowed to grow.
harder and concomitantly raise the level of ROS that would pre-
dispose them to oxidative stress-induced degeneration. Indeed,
in mice engineered to carry a mitochondrial-localized redox-
sensitive form of GFP, the basal oxidation as measured by this
reporter is significantly higher in SN dopaminergic neurons rel-
ative to their VTA counterparts. Importantly, the enhancement
of which can be lowered simply by the administration of L-type
Ca2+ channel antagonists into these transgenic mice (Guzman
et al., 2010). The“L-type Ca2+ hypothesis” is certainly an attractive
proposition to explain the unique vulnerability of SN dopaminer-
gic neurons toward degeneration. Moreover, neurons in the locus
ceruleus region that are also lost in the PD brain are similarly
autonomous pacemaker dependent on the activity of L-type Ca2+
channels (Williams et al., 1984). However, the hypothesis is not
an adequate explanation for all the susceptible sites in the PD
brain, which extend beyond the dopaminergic and noradrenergic
systems (Braak et al., 2003).
If the autophagy and UPS models of PD are supported by
disease-linked ATP13A2 and parkin mutations respectively, then
mutations in the redox-sensitive protein, DJ-1, which causes an
early-onset form of PD, would provide the genetic support for
the role of oxidative stress in PD pathogenesis. DJ-1 is thought to
operate as an atypical peroxiredoxin-like peroxidase that is capa-
ble of scavenging mitochondrial H2O2 (Canet-Aviles et al., 2004).
Consistent with this, increased levels of H2O2 in mitochondria can
be isolated from DJ-1 knockout mice (Andres-Mateos et al., 2007).
Notably, a pool of DJ-1 is known to be localized to the mitochon-
dria (Canet-Aviles et al., 2004; Zhang et al., 2005), suggesting a
functional link between DJ-1 and the organelle. Moreover, loss of
DJ-1 function promotes mitochondrial fragmentation in a vari-
ety of cells including lymphoblast cells derived from DJ-1 patients
and sensitizes them toward oxidative stress-induced death (Irrcher
et al., 2010; Krebiehl et al., 2010; Thomas et al., 2011), a phenotype
that can be rescued by restoration of functional DJ-1 expression
or by scavengers of ROS (Irrcher et al., 2010; Thomas et al., 2011).
Interestingly, a recent study suggest that DJ-1 enhances ERK-
dependent mitophagy in the presence of the parkinsonian neu-
rotoxin rotenone and in so doing protects dopaminergic neurons
against toxin-induced apoptosis (Gao et al., 2012). Accordingly, the
absence of DJ-1 may predispose dopaminergic neurons to mito-
chondrial dysfunction and oxidative stress-induced degeneration.
Indeed, DJ-1-deficient animals are hypersensitive to pharmaco-
logical inducers of oxidative stress (Kim et al., 2005; Menzies et al.,
2005; Meulener et al., 2005; Park et al., 2005; Yang et al., 2005;
Manning-Bog et al., 2007). Consistent with this, dopaminergic
neurons derived from in vitro differentiated DJ-1-deficient embry-
onic stem cells display decreased survival and increased sensitivity
to oxidative stress (Martinat et al., 2004). Importantly, the abla-
tion of DJ-1 expression results in the amplification of basal oxidant
stress in SN dopaminergic neurons (Guzman et al., 2010).
Finally, it is important to recognize that besides intrinsic sources
of ROS, oxidative radicals can also come extracellularly from
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activated glial cells, which is well documented in affected regions
of the PD brain, as well as in genetic and toxin-induced mod-
els of PD (Hald and Lotharius, 2005). Although glia-mediated
inflammatory events are often perceived as secondary to intrin-
sic events happening in susceptible neurons, they can aggravate
and/or perpetuate the pathogenic outcomes and as such may play
an instrumental role in promoting neuronal cell death. Indeed,
the role of neuro-inflammation is regaining its prominence in the
field as more and more researchers are now focusing on non-cell
autonomous forms of death in neurodegenerative diseases (for a
recent review, please refer to Hirsch et al., 2012).
CONCLUDING REMARKS – MAKING SENSE OUT OF THE
APPARENT CHAOS?
Most readers would agree after reading the description above that
the molecular events underlying PD pathogenesis is really com-
plex (Figure 3). Indeed, even the genes associated with PD, which
otherwise give the disease a tractable etiology, are so disparate
in function that at first sight, they seem to have little things (if
at all) in common. This is quite unlike the situation in Hunt-
ington’s disease, which can be traced to a single genetic defect
(i.e., mutations in the Huntingtin gene) or familial Alzheimer’s
disease where the majority of the disease-linked genes are clus-
tered around the amyloid precursor protein processing pathway.
Although disruptions in protein and mitochondrial QC are con-
sistently implicated in PD pathogenesis and are generally accepted
to be the key pathogenic drivers, additional pathogenic events that
have recently emerged (or are emerging) include aberrant pro-
tein phosphorylation, endosome recycling, and lipid metabolism
look set to complicate the picture. Furthermore, as we have dis-
cussed, the implicated pathways often act in a reciprocal fashion to
influence one another. Moreover, it is also becoming increasingly
clear that each of the PD-linked gene products, when dysfunc-
tional, can exert effects on multiple pathways either directly or
indirectly. Thus, no matter how upbeat one can be for a favored
PD-related pathway, it is highly unlikely to be the only pathway
involved in disease pathogenesis. To use an analogy regarding our
current knowledge about the molecular events underlying PD
pathogenesis – it seems like we are looking at a tapestry but on
its reverse side where all the different colored threads are interwo-
ven in a seemingly chaotic fashion. Undeniably, it is a significant
challenge to make sense out of the apparent chaos. Nonetheless,
we certainly have a better grasp of the pathogenic events happen-
ing in the PD brain these days than we have before as a result
of concerted efforts in the past decade or so by many investi-
gators around the world in unraveling the molecular causes of
the disease. Although we remain uncertain about the initiating
event, it is worthy to note that the myriad of pathways proposed
to be involved in disease pathogenesis appears to be converging
rather than diverging from each other. It is therefore perhaps not
surprising to see that various PD-linked genes with apparently
different function can directly or indirectly affect the same event
(e.g., mitochondrial dysfunction). Paradoxically, recognizing that
PD pathogenesis is a complex process may be the first step toward
understanding how the tapestry of pathogenic events is weaved
together.
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